Research Use Only: This article is for trained laboratory personnel and educational research context only. It summarizes in-vitro experiments and clearly identified laboratory animal-model studies.
It is not a home-use guide and must not be used for human, cosmetic, clinical, or veterinary administration or dose calculation.
KPV, as discussed in this article, is the free-acid tripeptide H-Lys-Pro-Val-OH. Its amino-acid sequence corresponds to residues 11–13 of α-melanocyte-stimulating hormone, although mature α-MSH has an amidated C terminus.

The free-acid form, KPV amide, D-amino-acid analogs, and salt forms have different molecular formulas, molecular weights, and terminal chemistries, and should not be treated as interchangeable. Published work has studied KPV in cell systems and laboratory mouse models, but those findings do not establish safety or effectiveness outside the tested research setting.[1][2][3]
Chemical Identity
| Sequence | H-Lys-Pro-Val-OH |
|---|---|
| Molecular formula | C16H30N4O4 |
| Average molecular weight | Approximately 342.43 g/mol |
| Monoisotopic mass | Approximately 342.2267 Da |
| Calculated [M+H]+ | Approximately m/z 343.234 |
| CAS number | 67727-97-3 |
These values apply to the free-acid form listed above.[1] H-Lys-Pro-Val-NH2 (KPV amide, PubChem CID 7019758, CAS 57899-80-6, molecular formula C16H31N5O3, molecular weight 341.45 g/mol, XLogP3 −1.8, TPSA 145 Ų) is the C-terminal amide and has a different formula and molecular weight from the free acid.[4]
Lys-D-Pro-Val (KdPV, PubChem CID 14552272, CAS 125905-17-1) contains D-proline; it has the same elemental composition and nominal molecular weight as all-L free-acid KPV (C16H30N4O4, 342.43 g/mol) but contains a different stereochemical configuration at the proline residue, and so the two forms should not be treated as interchangeable in laboratory studies.[5]
Purity, peptide content, water content, and counterion content are batch-specific attributes. Solubility behavior depends on the exact peptide form and experimental conditions (including pH, buffer, ionic strength, temperature, target concentration, and container material) and may also be influenced by batch attributes such as water content and salt form.
The exact material form and the lot-specific certificate of analysis should therefore be checked before any laboratory calculation.
What In-Vitro Studies Reported
Intestinal Epithelial and Immune-Cell Systems
Dalmasso and colleagues studied KPV in Caco2-BBE intestinal epithelial cells, HT29-Cl.19A cells, and Jurkat T cells. The experiments used NF-κB reporter assays, Western blotting, RT-PCR, ELISA, competition studies, and radiolabeled uptake measurements.[2]
In IL-1β-stimulated Caco2-BBE cells, the paper tested 10 nM KPV and reported lower NF-κB reporter activity, changes in IκBα degradation and phosphorylation, lower ERK, JNK, and p38 phosphorylation, and lower IL-8 mRNA and secreted IL-8 under the stated conditions.[2]
Uptake and competition experiments in the same study supported a role for the peptide transporter PepT1 in KPV entry into the tested Caco2-BBE and Jurkat cell systems. Parental HT29-Cl.19A cells served as a PepT1-negative comparison—they did not show the same KPV response—and the uptake and transfection experiments linked the observed KPV uptake and activity to PepT1 expression in the tested cell systems.[2]
These results apply to the named cell lines, stimuli, concentrations, and time points. They do not support one universal percentage reduction for every cytokine or cell type.
Bronchial Epithelial-Cell System
Land studied KPV in the immortalized human bronchial epithelial cell line 16HBE14o-. In that model, KPV was linked with changes in NF-κB reporter activity, IL-8, eotaxin, matrix metalloproteinase-9 activity, IκBα, and p65/RelA nuclear movement after TNF-α or RSV exposure under the conditions described in the study.[6]
The paper also reported intracellular and nuclear localization of KPV and competition data suggesting that KPV may interfere with the p65/RelA–importin-α3 interaction. The proposed contact with importin armadillo-repeat domains 7 and 8 came from competition and modeling work, not from a solved high-resolution structure.[6]
Separate research by Fagerlund et al. established that importin-α3 and importin-α4 are the main importin-α isoforms mediating TNF-α-stimulated NF-κB p50/p65 heterodimer translocation into the nucleus, with p50 binding to the N-terminal and p65 to the C-terminal NLS binding site of importin-α3.
NF-κB binds to importin-α only when free of IκBα.[7]
Important limit: The available studies support changes in measured NF-κB-related readouts. They do not prove that KPV directly inhibits IKK, binds one universal receptor, or works through one fully established molecular target.
What Laboratory Animal-Model Studies Reported
Dalmasso and colleagues also used DSS-induced and TNBS-induced laboratory mouse models. The study measured body-weight change, colon measurements, histology, myeloperoxidase activity, and cytokine mRNA in colon tissue.[2]
Kannengiesser and colleagues studied KPV in DSS-induced and CD45RBhigh-transfer laboratory mouse models and reported changes in weight-related, histological, and myeloperoxidase endpoints.[3]
These are preclinical model findings. They should be described by species, model, and measured endpoint and should not be rewritten as a human or veterinary outcome.
Formulation Studies
Laroui and colleagues placed KPV in nanoparticles combined with a polysaccharide hydrogel for a colon-targeted laboratory mouse-model study.[8] Xiao and colleagues studied hyaluronic-acid-functionalized KPV-loaded nanoparticles in cell experiments and a DSS-induced laboratory mouse model.[9]
Results from these engineered formulations cannot be assumed to apply to unformulated KPV or to a different carrier system.
What the Current Evidence Does Not Show
- It does not show that free-acid KPV, KPV amide, D-amino-acid analogs, salts, and nanoparticle formulations have the same behavior.
- It does not establish a fixed effect size across different cell lines, stimuli, concentrations, or assay methods.
- It does not support a broad claim that unmodified KPV always increases IL-10 or produces a defined M1-to-M2 macrophage shift.
- It does not establish human or veterinary safety, effectiveness, dosing, or an approved use.
How to Read a KPV Certificate of Analysis
A COA should separate identity, chromatographic purity, actual peptide content, water, counterion information, and relevant process impurities. A single purity number is not a complete description of the material.
For chemically synthesized peptides, specifications may also need to address sequence confirmation, individual and total related peptide impurities, deletion or insertion sequences, epimers, counterion content, process-related impurities, and other risks identified from the manufacturing process. ICH Q6A (adopted May 2000) provides guidance on the setting and justification of acceptance criteria and the selection of test procedures for new drug substances of synthetic chemical origin; its principles may be applied to low-molecular-weight synthetic peptides.
The EMA guideline on synthetic peptides (adopted December 2025, effective 1 June 2026) more specifically addresses peptide-related quality attributes including sequence confirmation, related peptide impurities, epimer/stereochemical control, residual solvents, elemental impurities, and process- and degradation-related risks.[10]
| COA item | What it tells you | Main limit |
|---|---|---|
| Mass spectrometry | Whether the observed molecular ion agrees with the expected molecular mass. | It does not by itself prove chromatographic purity, peptide content, salt form, sequence order, or stereochemical purity. |
| Sequence confirmation | Whether the amino-acid sequence and terminal modifications match the intended structure, when supported by interpretable MS/MS fragmentation, peptide mapping, NMR, Edman degradation, or another justified orthogonal method. | Amino-acid analysis alone confirms composition but does not independently confirm residue order or distinguish D/L configuration. |
| RP-HPLC purity | The relative peak area under the stated chromatographic method. | HPLC area percentage is not automatically the same as the mass percentage of peptide in the vial; individual and total related peptide impurities (including deletion, insertion, and truncation sequences) may require separate specification. |
| Peptide content | The measured or appropriately calculated amount of peptide in the material, using a suitable assay or justified mass-balance approach that accounts for water, counterions, and other relevant components. | It must not be assumed from HPLC purity alone; the calculation basis (e.g., as-is, dry basis, counterion-free basis) should be stated. |
| Water and counterion | Information needed for an accurate mass-based laboratory calculation. Counterion identification (e.g., acetate, TFA, chloride) and quantification should be included where applicable. | The result depends on the method and the actual salt form. |
| Stereochemical / epimer control | Whether a justified chiral or orthogonal method has been used to check for D-amino-acid epimers such as D-Pro when relevant to the intended research use. | Standard reversed-phase HPLC and intact-mass MS may not reliably distinguish KPV from KdPV or other epimers. |
| Residual solvents | Whether selected manufacturing solvents were checked under a stated method, with reporting limits linked to the solvents used or formed during synthesis, cleavage, purification, and lyophilization. | A claim such as “solvent-free” is not meaningful without a method, reporting limit, and acceptance criterion. |
Analytical methods should be suitable for their purpose. Current ICH Q2(R2) guidance covers validation features such as specificity, accuracy, precision, range, detection limit, and quantitation limit.[11]
Residual-solvent controls should be linked to the solvents that may remain from the manufacturing process and to an appropriate test method.[12]
COA conformity confirms only that the tested batch met the listed laboratory specifications. It does not prove human-use safety, veterinary-use safety, or clinical effectiveness.
Laboratory Handling Notes
Laboratory Configuration Warning: The points below are only for trained personnel preparing controlled in-vitro assays with calibrated laboratory equipment. They are not administration instructions and must not be converted into a human or veterinary dose.
- Confirm the exact sequence, terminal form, salt or counterion, molecular-weight basis, water result, and peptide content before calculating a stock concentration.
- Use the lot-specific COA and a small internal solubility check. Do not assume that one solvent, pH, or concentration works for every KPV form or every assay.
- Record the solvent, pH, nominal concentration, peptide-content correction, appearance, and final vehicle concentration in the experiment.
- Use a vehicle control and suitable positive, negative, and assay-performance controls.
- For lyophilized material, use the storage condition stated on the lot documentation. Where −20°C protection from light and moisture is specified, follow that instruction and document any deviation.
- Do not assign a shelf life to a prepared solution without supporting stability data. Temperature, light, moisture, and other conditions can affect material quality over time.[13]
No universal reconstitution concentration or solution-storage period is given here because those details depend on the exact material, assay, solvent, container, and supporting stability data.
Conclusion
KPV has been studied as a small research peptide in experiments involving PepT1 uptake, NF-κB, MAPK, cytokine readouts, and targeted formulation systems. The strongest conclusions are limited to the exact cell or laboratory animal model used in each paper.
Clear reporting of the peptide form, assay conditions, analytical method, and study model is essential. Claims that go beyond those details should be avoided.
References
- National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, MSH (11–13), L-lysyl-L-prolyl-L-valine. https://pubchem.ncbi.nlm.nih.gov/compound/Msh-_11-13
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. https://pubmed.ncbi.nlm.nih.gov/18061177/
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. https://pubmed.ncbi.nlm.nih.gov/18092346/
- National Center for Biotechnology Information. PubChem Compound Summary for CID 7019758, L-lysyl-L-prolyl-L-valinamide. https://pubchem.ncbi.nlm.nih.gov/compound/7019758
- National Center for Biotechnology Information. PubChem Compound Summary for CID 14552272, L-lysyl-D-prolyl-L-valine. https://pubchem.ncbi.nlm.nih.gov/compound/14552272
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012;4(2):59–73. https://pubmed.ncbi.nlm.nih.gov/22837805/
- Fagerlund R, Kinnunen L, Köhler M, Julkunen I, Melén K. NF-κB is transported into the nucleus by importin α3 and importin α4. Journal of Biological Chemistry. 2005;280(16):15942–15951. https://pubmed.ncbi.nlm.nih.gov/15677444/
- Laroui H, Dalmasso G, Nguyen HTT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853.e1–e2. https://pubmed.ncbi.nlm.nih.gov/19909746/
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628–1640. https://pubmed.ncbi.nlm.nih.gov/28143741/
- European Medicines Agency. ICH Q6A: Specifications — Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (Step 5, adopted May 2000). Applies to new drug substances of synthetic chemical origin; principles may apply to low-molecular-weight synthetic peptides. EMA ICH Q6A guideline
- European Medicines Agency. ICH Q2(R2): Validation of Analytical Procedures. EMA ICH Q2(R2) guideline
- European Medicines Agency. ICH Q3C: Residual Solvents (R9, current adopted version as of July 2026). EMA ICH Q3C guideline
- European Medicines Agency. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. EMA ICH Q1A(R2) guideline
Paper titles are kept in the reference list for bibliographic accuracy. Words used in a paper title do not turn a cell or laboratory animal-model result into an approved human, consumer, clinical, cosmetic, or veterinary application.
Research Use Only Disclaimer
Research Use Only: All SaiyanMed products are for laboratory research purposes only and not approved for human use. This article is provided for informational context regarding published laboratory in-vitro and animal-model research and general analytical-quality considerations only, and does not constitute medical, clinical, veterinary guidance or treatment advice.